An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at
 multiple centers in the United States.
This was a randomized, two double-blind (DB) treatment period dosing study.

 Previously diagnosed subjects with a history of episodic migraine (as defined by
 International Classification of Headache Disorders (ICHD), 3rd edition [beta version] [ICHD
 3]) who experienced an average of 2 to 8 migraine attacks per month for at least the prior 12
 months, with no more than 14 headache days per month, and with 48 hours of headache free time
 between migraine, were randomized in a 1:1 ratio in both DB periods to receive either DFN-02
 (sumatriptan nasal spray 10 mg) or a matching placebo.

 Subjects treated one moderate to severe migraine attack in the first double-blind treatment
 period (DB1) and, if eligible, were re-randomized into the second double-blind treatment
 period (DB2) to treat another migraine attack at any pain level.

 There was a screening period of up to 21 days to evaluate whether subjects fit the migraine
 inclusion criteria pursuant to ICHD-3, and did not have medication overuse. Subjects with at
 least a 12 month medical history of acute migraine were eligible for enrollment in the
 treatment period. Subjects continued to take their normal migraine medication during this
 screening period.

 If eligible and randomized, subjects in the DB1 treatment period were instructed to use the
 study medication in one migraine attack as soon as (and no more than within one hour after)
 experiencing moderate to severe migraine pain (defined as headache pain rating of Grade 2
 [moderate] or Grade 3 [severe] on a pain severity scale of 0 to 3). If the subject was not
 able to use study medication for the first migraine after randomization, they were instructed
 to use the study medication for the next attack. Those subjects who did not experience a
 migraine attack, and/or did not treat any migraine attack with study medication or record
 diary data, were not allowed to continue into the DB2 treatment period, and were
 discontinued.

 After treating a migraine attack with study medication, subjects were instructed to contact
 the site within 24 hours of the treated migraine (or the next working day) to schedule their
 next visit.

 Subjects returned to the study site within 2 to 7 days in the DB1 treatment period and, if
 continuing to be eligible, were re-randomized into a DB2 treatment period to treat one
 migraine attack at any pain level, and return to the study site within 2 to 7 days of the
 second treatment.

 Once randomized, the total duration of each subject's participation in the study was up to 10
 weeks.
Inclusion Criteria:

 1. A history of episodic migraine who experience an average of 2 to 8 migraine attacks
 per month for at least the past 12 months, with no more than 14 headache days per
 month, and with 48 hours of headache free time between migraine headaches

 2. Patients who have migraine with or without aura. If migraine with aura, the aura
 cannot last longer than 60 minutes.

 3. Patients who are willing and able to:

 1. Evaluate and record pain, migraine symptoms, and study medication effectiveness
 information in real-time using a diary for the duration of the study;

 2. Record each instance of the use of study medication and rescue medication in a
 patient diary in real-time for the duration of the study;

 3. Comply with all other study procedures and scheduling requirements.

 Exclusion Criteria:

 1. Minors, even if they are in the specified study age range

 2. Medication overuse:

 1. Opioids ≥ 10 days during the 90 days prior to screening

 2. Combination medications (e.g., Fiorinal®) ≥ 10 days during the 90 days prior to
 screening (only applies if combination medication contains an opioid and/or
 barbiturate)

 3. Nonsteroidal Anti-inflammatory Drugs or other simple medications ˃ 14 days a
 month during the 90 days prior to screening

 4. Triptans or ergots ≥ 10 days a month during the 90 days prior to screening

 3. Treated with onabotulinumtoxinA (Botox®) or other botulinum toxin treatment within 4
 months prior to screening for migraine prophylaxis (patients who were treated with
 same for cosmetic purposes may be allowed on a case-by-case basis after approval from
 the Medical Monitor)

 4. A history of or current neurological or psychiatric impairment, or cognitive
 dysfunction that, in the opinion of the Investigator, would compromise data collection

 5. Use of antipsychotics at least 15 days prior to randomization

 6. Patients who received treatment with an investigational drug or device within 30 days
 prior to randomization, or within 3 months if associated with central nervous system

 7. Patients who participated in a central nervous system clinical trial within 3 months
 prior to randomization

 8. Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface
 antigen (HBsAg), or hepatitis C virus (HCV) antibody serology testing

 9. Patients who are employees or immediate relatives of the employees of the Sponsor, any
 of its affiliates or partners, or of the clinical study research site